 Shares of Organon Co. OGN, -6.36 were down 6.7 in trading on Thursday after the company said it plans to acquire Forendo Pharma, a privately held company developing an endometriosis therapy. As part of the agreement, Organon will pay 75 million upfront, with an additional 879 million available in milestone payments. 